Literature DB >> 20155338

Multicentric primary intestinal EBV-positive diffuse large B cell lymphoma of the elderly presenting with perforation.

Shih-Sung Chuang1, Ryo Ichinohasama, Chun-Chieh Yang, Wen-Ching Wang, Chung-Kuao Chou, Yung-Liang Liao, Szu-Yin Kuo, Shu-Hui Lin.   

Abstract

Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) of the elderly is a recently defined subgroup of DLBCL in the 2008 WHO classification of lymphoid neoplasms. It is characterized by an EBV-positive clonal B cell lymphoproliferation that occurs in patients aged over 50 years without any known immunodeficiency. This disease shows frequent extranodal involvement, a morphological spectrum from polymorphous to monomorphic large cells, and a poor prognosis. We reported the case of a 75-year-old male who had a primary intestinal multicentric EBV(+) DLBCL and presented with perforation, the first multicentric case in the literature. The monomorphic tumor cells exhibited extensive necrosis and expressed CD20, CD138, and EBNA2 with diffuse positivity for EBV by in situ hybridization. Quantitative real-time PCR revealed a low serum EBV viral load. The patient passed away in 10 days. His poor outcome was probably due to perforation, age over 70, the presence of B symptoms, poor general condition, and high performance score.

Entities:  

Mesh:

Year:  2010        PMID: 20155338     DOI: 10.1007/s12185-010-0512-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.

Authors:  Wing-Yan Au; Annie Pang; Carolyn Choy; Chor-Sang Chim; Yok-Lam Kwong
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

2.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Authors:  A A Brink; D F Dukers; A J van den Brule; J J Oudejans; J M Middeldorp; C J Meijer; M Jiwa
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

3.  Monoclonality in B-lymphoproliferative disorders detected at the DNA level.

Authors:  K J Trainor; M J Brisco; C J Story; A A Morley
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

Review 4.  Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.

Authors:  Yoshie Shimoyama; Takashi Oyama; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2006-03

5.  The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.

Authors:  Sarah Park; Jeeyun Lee; Young Hyeh Ko; Arum Han; Hyun Jung Jun; Sang Chul Lee; In Gyu Hwang; Yeon Hee Park; Jin Seok Ahn; Chul Won Jung; Kihyun Kim; Yong Chan Ahn; Won Ki Kang; Keunchil Park; Won Seog Kim
Journal:  Blood       Date:  2007-03-30       Impact factor: 22.113

Review 6.  Epstein Barr virus-associated tumours: an update for the attention of the working pathologist.

Authors:  H-J Delecluse; R Feederle; B O'Sullivan; P Taniere
Journal:  J Clin Pathol       Date:  2007-09-14       Impact factor: 3.411

Review 7.  EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate.

Authors:  Shih-Chuan Hsiao; Ryo Ichinohasama; Shu-Hui Lin; Yung-Liang Liao; Sheng-Tsung Chang; Chi-Yi Cho; Shih-Sung Chuang
Journal:  Pathol Res Pract       Date:  2008-10-31       Impact factor: 3.250

8.  Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.

Authors:  Takashi Oyama; Kazuhito Yamamoto; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Kengo Takeuchi; Toshiyuki Izumo; Shigeo Mori; Koichi Ohshima; Junji Suzumiya; Naoya Nakamura; Masafumi Abe; Koichi Ichimura; Yumiko Sato; Tadashi Yoshino; Tomoki Naoe; Yoshie Shimoyama; Yoshikazu Kamiya; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

Review 9.  Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  Sherif A Rezk; Lawrence M Weiss
Journal:  Hum Pathol       Date:  2007-09       Impact factor: 3.466

10.  Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients.

Authors:  Takashi Oyama; Koichi Ichimura; Ritsuro Suzuki; Junji Suzumiya; Koichi Ohshima; Yasushi Yatabe; Takio Yokoi; Masaru Kojima; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Michinori Ogura; Hidehiko Saito; Yasuo Morishima; Shigeo Nakamura
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  5 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  EBV-positive diffuse large B-cell lymphoma of the elderly.

Authors:  Chi Young Ok; Thomas G Papathomas; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

3.  Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis.

Authors:  Xiaojuan Gao; Jia Li; Yaqi Wang; Shuai Liu; Baohong Yue
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

4.  Mapping of human papilloma virus, p16, and epstein-barr virus in non-malignant tonsillar disease.

Authors:  Anna Holm; Alexandra Schindele; Annika Allard; Irene Eriksson; Karl Sandström; Göran Laurell; Karin Nylander; Katarina Olofsson
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-04-12

5.  EBV-positive diffuse large B-cell lymphoma in a patient with primary Sjögren's syndrome and membranous glomerulonephritis.

Authors:  Chang Seong Kim; Yoo Duk Choi; Joon Seok Choi; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  BMC Nephrol       Date:  2012-11-15       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.